N. Brownlow

发表

FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance

J. Taylor, J. Domin, N. Brownlow, 2006, Oncogene.

Protein kinase C epsilon in cell division: Control of abscission

P. Parker, A. Saurin, N. Brownlow, 2009, Cell cycle.

Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis

M. Wiesmann, P. Manley, N. Brownlow, 2008, Leukemia.

Mitotic catenation is monitored and resolved by a PKCε-regulated pathway

L. Collinson, P. Parker, D. Zicha, 2014, Nature Communications.

STAT4 expression and activation is increased during mitosis in vitro and in vivo in skin‐ and mucosa‐derived cell types: implications in neoplastic and inflammatory skin diseases

E. Healy, C. Ferreli, Y. Buggy, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Regulation of the cytokinesis cleavage furrow by PKCε.

P. Parker, J. Claus, N. Brownlow, 2014, Biochemical Society transactions.

Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro

N. Brownlow, N. Dibb, M. Vaid, 2008, Leukemia.

DNA replication stress: NoCut to the rescue

M. Mendoza, Nuno Amaral, N. Brownlow, 2017, Cell cycle.

Novel Imatinib Derivatives with Altered Specificity between Bcr–Abl and FMS, KIT, and PDGF Receptors

S. Kiriakidis, A. Tzakos, N. Dibb, 2010, ChemMedChem.

Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor

C. Mol, S. Ghaem-Maghami, N. Brownlow, 2008, Leukemia.

PKCɛ switches Aurora B specificity to exit the abscission checkpoint

Jeremy G. Carlton, P. Parker, J. Carlton, 2016, Nature Communications.

The Aurora B specificity switch is required to protect from non-disjunction at the metaphase/anaphase transition

F. Fraternali, P. Parker, S. Jamshidi, 2020, Nature Communications.